Item | Proposed method | Reported method [17] | Reported method [18] | Reported method [19] |
---|---|---|---|---|
Technique | HPLC–UV | HPLC–UV | HPLC–UV | HPLC–UV |
Matrix | Human plasma | Nano-formulation | Rabbit Plasma | Nano-formulation |
Optimization strategy | Central Composite Design | Full factorial design | Full factorial design | One factor at a time |
Mobile phase | Methanol: 0.05Â M phosphate buffer, pH 3 (64.5:35.5, v/v) | Acetonitrile: 20Â mM ammonium formate, pH 3 (43:57, v/v) | Acetonitrile: 20Â mM ammonium formate (42:58 v/v) | Acetonitrile: 10Â M phosphate buffer, pH 3.6 (60:40, v/v) |
Analytes | XIP and VAL | VAL | VAL | VAL |
LOD (ng/mL) | 134 | 4.833 | 22.000 | 6.000 |
LOQ (ng/mL) | 448 | 44.95 | 66.67 | 25 |
Retention time (min) | 4.34 | 10.177 | 11.394 | 2.91 |
% Recovery ± SD | 89.17 ± 7.38 |  | 94.81 ± 9.80 |  |
n | 4 | Â | 3 | Â |
V | VAL: 54.47 | Â | 96.13 | Â |
t | 0.835 (2.571)a | Â | Â | Â |
F | 1.765 (9.53)b | Â | Â | Â |